Literature DB >> 31997083

Disease activity-based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade.

Marieke J Spijk-de Jonge1, Julia M Weijers2, Marlies E J L Hulscher1, Piet L C M van Riel1,3, Laura W M Boerboom4, Anita M P Huis1, Femke Atsma1, Laura T C Van Hulst5, Mart A F J van de Laar6.   

Abstract

To re-evaluate the adherence to clinical practice guidelines recommended disease activity-based management of rheumatoid arthritis (RA) in daily clinical practice, among Dutch rheumatologists in the past decade. In 2007, disease activity was measured in only 16% of outpatient visits. All rheumatologists that participated in the 2007 study were invited to re-enter our study in 2016/2017. If necessary, data were supplemented with data from other rheumatologists. For all 26 rheumatologists who agreed to participate in our study, data were collected from 30 consecutive patients that visited the outpatient clinic. Per patient, data from four consecutive rheumatologist outpatient visits were collected. Since 2007, disease activity was measured more frequently in Dutch daily clinical practice, increasing from 16 to 79% of visits (2440/3081 visits). In addition, intensification of medication based on disease activity scores increased from 33 to 50% of visits (260/525 visits). DAS/DAS28 was the most frequently used disease activity measure (1596/2440 visits). There was a wide variation among rheumatologists in measuring disease activity and intensification of medication, 20-100% and 0-75% respectively. Over the past years, there has been a large improvement in disease activity assessment in daily clinical practice. Disease activity-based medication intensifications, also called tight control or treat to target, increased to a lesser extent. Large variation between different rheumatologists and clinics indicates that there is still room for improvement. Key Points • Following guideline dissemination disease activity is assessed more frequently (79%). • There is large variation between rheumatologists, indicating room for improvement. • Finding factors that explain variation is necessary to improve tight control in daily practice.

Entities:  

Keywords:  Clinical practice guidelines; Disease activity; Rheumatoid arthritis; Tight control; Variation

Mesh:

Substances:

Year:  2020        PMID: 31997083     DOI: 10.1007/s10067-019-04913-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.

Authors:  Leslie R Harrold; J Timothy Harrington; Jeffrey R Curtis; Daniel E Furst; Mary Jane Bentley; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg
Journal:  Arthritis Rheum       Date:  2012-03

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.

Authors:  Yvonne van Eijk-Hustings; Astrid van Tubergen; Carina Boström; Elena Braychenko; Beate Buss; José Felix; Jill Firth; Alison Hammond; Benny Harston; Cristina Hernandez; Masa Huzjak; Jana Korandová; Marja Leena Kukkurainen; Robert Landewé; Maryse Mezieres; Marijana Milincovic; Antonella Moretti; Susan Oliver; Jette Primdahl; Marieke Scholte-Voshaar; Jenny de la Torre-Aboki; Jennifer Waite-Jones; Rene Westhovens; Heidi Andersen Zangi; Turid Heiberg; Jackie Hill
Journal:  Ann Rheum Dis       Date:  2011-10-28       Impact factor: 19.103

4.  Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice.

Authors:  Tal Gazitt; Shirley Oren; Tatiana Reitblat; Merav Lidar; Alexandra Balbir Gurman; Itzhak Rosner; Nimer Halabe; Joy Feld; Sameer Kassem; Idit Lavi; Ori Elkayam; Devy Zisman
Journal:  Eur J Rheumatol       Date:  2019-05-20

5.  Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.

Authors:  J Fransen; H Bernelot Moens; I Speyer; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 6.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

7.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).

Authors:  S M M Verstappen; J W G Jacobs; M J van der Veen; A H M Heurkens; Y Schenk; E J ter Borg; A A M Blaauw; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

8.  DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; P J S M Kerstens; M M J Nielen; K Vos; D van Schaardenburg; I Speyer; P E H Seys; F C Breedveld; C F Allaart; B A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Authors:  Laura M M Steunebrink; Harald E Vonkeman; Peter M ten Klooster; Monique Hoekstra; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

Review 10.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.